RT Journal Article
SR Electronic
T1 How deep brain stimulation and levodopa affect gait variability in Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.07.20207704
DO 10.1101/2020.10.07.20207704
A1 Zi Su
A1 Salil Patel
A1 Bronwyn Gavin
A1 Tim Buchanan
A1 Marko Bogdanovic
A1 Nagaraja Sarangmat
A1 Alexander L. Green
A1 Tipu Z. Aziz
A1 James J. FitzGerald
A1 Chrystalina A. Antoniades
YR 2020
UL http://medrxiv.org/content/early/2020/10/09/2020.10.07.20207704.abstract
AB Background Disorders of gait are a very common feature of Parkinson’s Disease. We examined how deep brain stimulation of the subthalamic nucleus (STN DBS) and dopaminergic medication affect gait and more specifically its rhythmicity.Objectives We accurately quantified multiple gait parameters in Parkinson’s patients during on and off stages of their treatment (levodopa or STN DBS) to compare and contrast the treatment-induced changes in gait.Methods We studied 11 patients with STN DBS, 15 patients on levodopa and 42 healthy controls. They all completed the MDS-UPDRS part III along with a gait assessment protocol while wearing six nine-axis inertial measurement units (lumbar, sternal, and all four extremities).Results Both medication and stimulation significantly improved stride length, while medication further significantly increased gait speed. In the lower limbs, both medication and stimulation had a normalising effect on lower limb angles, significantly increasing the foot strike angle and toe-off angle.Conclusions STN DBS reduced the step to step variability in a range of lower limb gait parameters in PD, while antiparkinsonian medication had no significant effect. This suggests that STN stimulation, but not dopaminergic medication, has access to circuits that control gait rhythm, and that the resulting effect of stimulation on gait is beneficial. However, the results we observed for movement of the trunk and upper limbs were strikingly different to those seen in the lower limbs. We propose a hypothesis to explain why we observe these results, focusing on cholinergic pedunculopontine projections.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04139551Funding StatementThis was study was funded by a grant from UCB Biopharma SRL JJF was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the ethics committee (REC reference 16/SW/0262) Oxford University Trust. UKAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnyone interested in the data can email directly to apply for it.